about
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.[Antiphospholipid syndrome and preeclampsia].Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue.Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinraMicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritisPTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis.Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis.Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritisObesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.Biological therapies in autoimmune chronic inflammatory diseases (ACIDs).Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid ArthritisTapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective studyAllele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis.MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis.The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU).ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature.Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections.The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk.Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis.Should we consider tumor necrosis factor as the only target in spondyloarthritides?Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus.Position paper of Italian rheumatologists on the use of biosimilar drugs.Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years.Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations.Using a modified Delphi process to establish clinical consensus for the diagnosis, risk assessment and abatacept treatment in patients with aggressive rheumatoid arthritis.Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment.Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YESSynovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?Validation of the classification criteria for cryoglobulinaemic vasculitis.Incidence of cancer in patients with spondyloarthritis treated with anti-tnf drugs.
P50
Q30662067-35F8EB0F-83C2-4CDF-82E1-DBCEE35134CCQ30967810-D56078D2-3B4B-479B-A90D-609D59539F9CQ31078960-CC3948CF-EBCC-40E7-9511-347404C48535Q33375506-AE1AE6AA-4C7F-4E77-9185-6ABBBCD454D2Q33766304-9B936BA8-2F94-4824-BFB2-6190AD754331Q33817997-93E5FF49-EB7B-4561-B8D4-D367F8B9ECB5Q33849824-85FB5829-5E5F-4903-B8CE-3FBBCCAA1A7FQ34031304-458AADA7-24CF-4BE8-8F2B-5E6EC82086A7Q34208191-96BFB6F0-9084-4224-9634-B6807B6018F5Q34274249-F68248D0-5397-4797-9F17-C10DDBE93FADQ34488394-61388675-2FFC-473B-9C8B-BF7235785912Q35012150-E0E013FD-7B83-45EC-9D14-3BBECA6A48D1Q35286950-FC688276-2A5E-4779-9277-B69A65688F03Q35832290-394F3949-B95B-4C91-841B-9E9939FAA0CFQ36403567-02CCB3A9-861F-4F9B-B29A-BC907DF4F6E0Q36437722-87ACD39B-3F70-44F5-928C-9E47922FAF38Q36543127-58A89BE6-213C-4D26-9128-E783E4AD6046Q36876782-A71B2407-59E1-4BE1-9804-74015FB2C3EFQ37079254-CE512188-FBF0-4516-968D-C21E8F5D9781Q37315021-02AC78C0-B46D-4AC2-B3C1-F3E401574A36Q37467895-5618388E-9CB3-4DBA-BBB9-1072295BD78BQ37626889-22A89E77-FAF1-42F0-A7A7-6CC1087E8F34Q37867516-EA7F5C12-B4AF-476A-B4BE-BB0199E5A59BQ37871668-35E7DDA7-4515-41A4-9E04-5635E6901DACQ37880678-0B394273-AD8E-4B4B-B4FF-700E7F43084EQ38023176-041CF1C9-31D0-433D-9A06-1E621C868FDEQ38262100-2CCC1D49-5287-4C15-9F0B-688CED889BD4Q38273131-E4A1E0CE-C33A-44A5-A1FC-E7B75D4A33FAQ38406712-622DA111-37A0-4F08-A1E1-479F68189955Q38414103-A7B3FC60-4508-43AC-8D00-65B3C393C221Q38437664-9F595953-0DF1-4E1A-A444-8DD3D7373E43Q38622079-C9FB693A-FC61-463B-A55A-D5EC6A0B2755Q38703626-518FC20E-7B55-4963-801B-6588AABF1B4AQ38763702-EFA0CEEA-41CB-47B2-B68A-439B41DACEEDQ38915325-BABF0667-0DDE-47FA-A2D8-C08A1968C09BQ39446763-399BFF9D-7D31-4A5B-A136-85ED9C9F8AF3Q39834837-D2DE0632-0F0C-46E8-9F9A-6F6CE0428B5AQ41146155-66C772E2-E8AF-4AC2-839F-DC0ABE385A95Q42208172-65B7A338-90E4-4A55-95EE-C5D057DEA01BQ42689661-71EB7E2D-D59E-4C1E-BD3D-17895FB7F1A3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elisa Gremese
@ast
Elisa Gremese
@en
Elisa Gremese
@es
Elisa Gremese
@nl
Elisa Gremese
@sl
type
label
Elisa Gremese
@ast
Elisa Gremese
@en
Elisa Gremese
@es
Elisa Gremese
@nl
Elisa Gremese
@sl
prefLabel
Elisa Gremese
@ast
Elisa Gremese
@en
Elisa Gremese
@es
Elisa Gremese
@nl
Elisa Gremese
@sl
P106
P21
P31
P496
0000-0002-2248-1058